|
|
Article: Iressa does not prolong life, may cause bleeding in head and neck cancer patients.(Recalls/Warnings)
- Article from:
- Adverse Event Reporting News
- Article date:
- May 21, 2007
CopyrightCOPYRIGHT 2007 Washington Information Source, Inc. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
AstraZeneca Canada, in consultation with Health Canada, has alerted patients in the Iressa Patient Registry (IPR) Program of new information from a clinical trial on the use of Iressa in patients who have head and neck cancer. Although head and neck cancer is not an approved use for Iressa, patients with this diagnosis may be participating in the IPR Program if benefiting from therapy.
In a large clinical trial in patients with head and neck cancer, patients received Iressa 250 mg, Iressa 500 mg or methotrexate chemotherapy, to compare how long head and neck cancer patients lived if they were treated with Iressa or methotrexate. Results from the study showed that ...